Obiettivo Cancer is a genetic as well an epigenetic disease. A prominent epigenetic alteration is DNA-methylation in the promoter region of the gene that prevents the gene to be expressed. Recently high-throughput methods to analyze the methylation status of genes in a large number of samples simultaneously have been developed. Now, even global DNA-methylation can be studied using stable tumor DNA preparations, rather than the labile RNA preparations required for cDNA microarray analyses. This way, new target genes, which provide the basis to improve treatment strategies, can be discovered. With the aim to catch up with the current genomic information and to implement the epigenetic DNA-methylation analyses in the clinical setting, we formed the present consortium encompassing members of the European Union and associated member states to take a multidisciplinary and innovative approach to study DNA-methylation of breast tumors in order to improve prognosis and treatment possibilities of the patients. The participating centers contribute complementary state-of-the-art proprietary technical expertise, large and well-documented tissue resources, and intense clinical expertise. Recently, members of this consortium have developed epigenetic predictive signatures for breast cancer patients treated with endocrine therapy. This proof-of-principle is the basis for the breast cancer studies proposed in the present project and the main objectives are: 1) By genome-wide DNA-methylation screening identify new therapeutic targets. 2) Develop prognostic and predictive DNA-methylation markers. 3) Confirm these findings at the mRNA and protein level, and in clinically relevant subgroups of breast cancer. 4) Commercialize relevant target genes discovered for prognostic, predictive and therapeutic use. Achievements expected are the improvement of patient prognosis by development of better therapeutic approaches based on new targeted therapies and better therapy selection. Campo scientifico natural sciencesbiological sciencesgeneticsDNAnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineoncologybreast cancernatural sciencesbiological sciencesgeneticsRNAnatural sciencesbiological sciencesgeneticsepigenetics Parole chiave DNA methylation breast cancer risk assessment target genes therapy selection Programma(i) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) LSH-2002-2.2.0-8 - Translational research on promising predictive and prognostic markers Invito a presentare proposte FP6-2002-LIFESCIHEALTH Vedi altri progetti per questo bando Meccanismo di finanziamento STREP - Specific Targeted Research Project Coordinatore ERASMUS MEDICAL CENTER ROTTERDAM Contributo UE Nessun dato Indirizzo Dr. Molewaterplein, 50 ROTTERDAM Paesi Bassi Mostra sulla mappa Costo totale Nessun dato Partecipanti (8) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto TECHNICAL UNIVERSITY OF MUNICH Germania Contributo UE Nessun dato Indirizzo Ismaninger Strasse, 22 MUNICH Mostra sulla mappa Costo totale Nessun dato DEN KONGELIGE VETERINAER- OG LANDBOHOEJSKOLE (ROYAL VETERINARY AND AGRICULTURAL UNIVERSITY) Danimarca Contributo UE Nessun dato Indirizzo Buelowsvej, 17 FREDERIKSBERG C. Mostra sulla mappa Costo totale Nessun dato STICHTING KATHOLIEKE UNIVERSITEIT Paesi Bassi Contributo UE Nessun dato Indirizzo Geert Grooteplein, 10 NIJMEGEN Mostra sulla mappa Costo totale Nessun dato EPIGENOMICS AG AND EPIGENOMIC INC Germania Contributo UE Nessun dato Indirizzo Kastanienallee 24 BERLIN Mostra sulla mappa Costo totale Nessun dato CENTRE RENE HUGUENIN Francia Contributo UE Nessun dato Indirizzo Rue Dailly, 35 ST CLOUD Mostra sulla mappa Costo totale Nessun dato INSTITUT OF ONCOLOGY LJUBLJANA Slovenia Contributo UE Nessun dato Indirizzo Zaloska, 2 LJUBLJANA Mostra sulla mappa Costo totale Nessun dato NATIONAL UNIVERSITY OF IRELAND, DUBLIN Irlanda Contributo UE Nessun dato Indirizzo Belfield DUBLIN Mostra sulla mappa Costo totale Nessun dato STIFTUNG TUMORBANK BASEL Svizzera Contributo UE Nessun dato Indirizzo Loerrachestrasse, 50 RIEHEN Mostra sulla mappa Costo totale Nessun dato